Anexelekto (Axl)/Mer Inhibitor Tamnorzatinib in Patients with Relapsed/Refractory Acute Myeloid Leukaemia: Results from a Phase I (Monotherapy) and Phase II (Combination with Venetoclax) Clinical Study
Tamnorzatinib alone and in combination with venetoclax was safe and well tolerated but failed to induce robust clinical efficacy in R/R AML.
Authors
- Mary L. McBride (ORCID: https://orcid.org/0000-0003-1559-7420)
- Courtney Denton Dinardo (ORCID: https://orcid.org/0000-0001-9003-0390)
- Robert K. Stuart (ORCID: https://orcid.org/0000-0001-7549-8008)
- Takaaki Nakamura
- Nigel Courtenay-Luck
- Praneeth Baratam (ORCID: https://orcid.org/0000-0002-3129-9047)
- Akifumi Fujii
- Honda Naoki (ORCID: https://orcid.org/0000-0001-6816-9126)
- Margaret Kasner (ORCID: https://orcid.org/0000-0001-8616-744X)
- Sean M. Post (ORCID: https://orcid.org/0000-0001-9225-200X)
- George N. Magrath (ORCID: https://orcid.org/0000-0002-2416-0821)
- S. Prados
- Paula Edwards-Holmes
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Thomas Jefferson University (US)
- Medical University of South Carolina (US)
- Sidney Kimmel Cancer Center (US)
- Acceleron Pharma (United States) (US)
- Ono Pharmaceutical (Japan) (JP)
- AMO Pharma (United Kingdom) (GB)
Publication Details
- Journal
- Acta Haematologica
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1159/000549340
- Citations
- 1
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Ono Pharmaceutical